It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models. The consensus rating for Lexicon is "Buy", based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results